Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
This article reviews the FDC of canagliflozin with metformin extended release.AREAS COVERED: A literature search was performed to identify publications describing the efficacy and safety of canagliflozin and metformin when used separately and in combinations.EXPERT OPINION: Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which has shown benefits in reducing progression of renal disease and heart failure in patients with T2D. There was an increased incidence of amputation with canagliflozin in one study, but canagliflozin results in weight loss and reduction of blood pressure which contribute to the over...
Source: Expert Opinion on Pharmacotherapy - October 26, 2023 Category: Drugs & Pharmacology Authors: Brian Tomlinson Yan-Hong Li Source Type: research
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
This article reviews the FDC of canagliflozin with metformin extended release.AREAS COVERED: A literature search was performed to identify publications describing the efficacy and safety of canagliflozin and metformin when used separately and in combinations.EXPERT OPINION: Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which has shown benefits in reducing progression of renal disease and heart failure in patients with T2D. There was an increased incidence of amputation with canagliflozin in one study, but canagliflozin results in weight loss and reduction of blood pressure which contribute to the over...
Source: Expert Opinion on Pharmacotherapy - October 26, 2023 Category: Drugs & Pharmacology Authors: Brian Tomlinson Yan-Hong Li Source Type: research
Ivosidenib in acute myeloid leukemia
Expert Opin Pharmacother. 2023 Oct 24:1-8. doi: 10.1080/14656566.2023.2272659. Online ahead of print.ABSTRACTINTRODUCTION: Traditional treatment strategies for acute myeloid leukemia (AML) have primarily relied on standard chemotherapy regimens for four decades. Indeed, the landscape of AML therapy has evolved substantially in recent years, mainly due to the introduction of hypomethylating agents and small molecules.Bcl2 inhibitor venetoclax, Fms-like tyrosine kinase 3 (FLT3) inhibitors such as midostaurin and gilteritinib, and isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) inhibitors ivosidenib and enasidenib, as well ...
Source: Expert Opinion on Pharmacotherapy - October 24, 2023 Category: Drugs & Pharmacology Authors: Antonella Bruzzese Caterina Labanca Enrica Antonia Martino Francesco Mendicino Eugenio Lucia Virginia Olivito Antonino Neri Annalisa Imovilli Fortunato Morabito Ernesto Vigna Massimo Gentile Source Type: research
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension
Expert Opin Pharmacother. 2023 Oct 23. doi: 10.1080/14656566.2023.2273395. Online ahead of print.ABSTRACTINTRODUCTION: Pulmonary arterial hypertension (PAH) is a severe, progressive pulmonary vasculopathy (Group 1 Pulmonary Hypertension (PH 1)) that complicates the course of many connective tissue diseases (CTD) and significantly impacts the quality and length of life of patients. Due to the various tissues that can be affected by CTD, detailed testing is required to differentiate true PAH from other types of pulmonary hypertension caused by CTD such as left heart disease (Group 2 PH), pulmonary parenchymal disease (Group ...
Source: Expert Opinion on Pharmacotherapy - October 23, 2023 Category: Drugs & Pharmacology Authors: Mithum Kularatne Ath énaïs Boucly Laurent Savale Sabina Solinas C éline Cheron Anne Roche Mitja Jevnikar Xavier Ja ïs David Montani Marc Humbert Olivier Sitbon Source Type: research
